Onconova Therapeutics (ONTX) Stock Price, News & Analysis

Company Overview

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.67 to $1.01
• 52-Week Range: N/A
• Volume: 1.28 million shs
• Average Volume: 96,681 shs
• Market Capitalization: $20.90 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ONTX Stock Analysis - Frequently Asked Questions

How were Onconova Therapeutics' earnings last quarter?

Onconova Therapeutics, Inc. (NASDAQ:ONTX) posted its quarterly earnings results on Thursday, November, 11th. The biopharmaceutical company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.11. The biopharmaceutical company earned $0.06 million during the quarter, compared to analysts' expectations of $0.06 million. Onconova Therapeutics had a negative trailing twelve-month return on equity of 95.43% and a negative net margin of 8,930.97%.

When did Onconova Therapeutics' stock split?

Onconova Therapeutics's stock reverse split before market open on Friday, May 21st 2021.The 1-15 reverse split was announced on Thursday, May 20th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 20th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Onconova Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Onconova Therapeutics investors own include Tonix Pharmaceuticals (TNXP), Ocugen (OCGN), Bionano Genomics (BNGO), NIO (NIO), OPKO Health (OPK), Sorrento Therapeutics (SRNE) and FuelCell Energy (FCEL).

Company Calendar

• Last Earnings: 11/11/2021
• Today: 8/27/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ONTX
• CIK: 1130598
• Web: www.onconova.com
• Phone: (267) 759-3680
• Fax: 267-759-3681
• Employees: 16
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.91)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$18.96 million
• Net Margins: -8,930.97%
• Pretax Margin: -8,930.97%
• Return on Equity: -95.43%
• Return on Assets: -61.19%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.79
• Quick Ratio: 2.79

Sales & Book Value

• Annual Sales: $230 thousand
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.35 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 21,000,000
• Free Float: 20,310,000
• Market Cap: $20.90 million
• Optionable: Optionable
• Beta: 1.38